Related Experiment Video

Updated: May 16, 2025

Author Spotlight: Scope of LE-ULBD as a Safe, Effective, and Minimally Invasive Approach to Treat Lumbar Spinal Stenosis
05:17

Author Spotlight: Scope of LE-ULBD as a Safe, Effective, and Minimally Invasive Approach to Treat Lumbar Spinal Stenosis

Published on: February 9, 2024

457

Letter: Lubiprostone Treatment for MASLD-Gender Imbalance and Blinding Considerations. Authors' Reply

Mohamed El-Kassas1,2, Hala Mostafa1, Hongqun Liu3

  • 1Endemic Medicine Department, Faculty of Medicine, Helwan University, Cairo, Egypt.

Alimentary Pharmacology & Therapeutics
|April 4, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
MASHMASLDclinical trial designlubiprostone

More Related Videos

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction05:00

Intense Pulsed Light for the Treatment of Dry Eye Owing to Meibomian Gland Dysfunction

Published on: April 1, 2019

14.8K
How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants08:50

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

Published on: December 14, 2014

9.2K

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
117
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
126